Everything below concerns Selank. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-23. Numbers and descriptions here follow the published literature rather than marketing material.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
=== Legal status === Takeda filed a marketing authorisation application in the European Union on 7 March 2013 and a biologic license application (BLA) with the U.S. Food and Drug Administration on 21 June 2013 for both Crohn's disease and ulcerative colitis. On 4 September 2013, vedolizumab was given a Priority Review Status, which functions to expedite potential acceptance to market. In March 2014, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for vedolizumab (brand name Entyvio). In May 2014, vedolizumab (Entyvio) was approved by the FDA for treatment of both moderate-to-severe ulcerative colitis and moderate-to-severe Crohn's disease. In May 2014, Entyvio was approved for medical use in the European Union. In April 2015, Health Canada approved Entyvio.
=== Diabetes === Cellular uptake of glucose occurs in response to insulin signals, and glucose is subsequently broken down through glycolysis, lowering blood sugar levels. However, insulin resistance or low insulin levels seen in diabetes result in hyperglycemia, where glucose levels in the blood rise and glucose is not properly taken up by cells. Hepatocytes further contribute to this hyperglycemia through gluconeogenesis. Glycolysis in hepatocytes controls hepatic glucose production, and when glucose is overproduced by the liver without having a means of being broken down by the body, hyperglycemia results.
== See also == All pages with titles beginning with Thin All pages with titles containing Thin Body shape Emaciation Underweight Paper Thin (disambiguation) Thin capitalisation Thin client, a computer in a client-server architecture network. Thin film, a material layer of about 1 μm thickness. Thin-layer chromatography (TLC), a chromatography technique used in chemistry to separate chemical compounds Thin layers (oceanography), congregations of phytoplankton and zooplankton in the water column Thin lens, lens with a thickness that is negligible compared to the focal length of the lens in optics Thin Lizzy, Irish rock band formed in Dublin in 1969 Thin Man (disambiguation) The Thin Blue Line (disambiguation)
== TV == Floyd on Fish, BBC TV, 1985 Floyd on Food, BBC TV, 1986 Farmhouse Kitchen, Yorkshire Television, two episodes, 1989 and 1990 Taste of the Sea, BBC TV, 1995. 6 episodes – Glenfiddich TV Programme of the Year Award, Good Food Award Television Cookery Programme of the Year Fruits of the Sea, BBC TV, 1997. 8 episodes – Silver Medal World Food Media Awards Adelaide 1997 Great Railway Journeys, BBC TV, 1999 (Los Mochis to Veracruz) Rick Stein's Seafood Odyssey, BBC TV, 1999. 8 episodes – Bronze Medal World Food Media Awards Adelaide 1999 Fresh Food, BBC TV, 1999. 6 episodes Personal Passions, BBC TV, 1999 Food and Drink, BBC TV, 1999 – Gold Award for Best Television Food Segment Within a Show: World Food Media Awards Adelaide 1999 Rick Stein's Seafood Lovers' Guide, BBC TV, 2000. 8 episodes – Glenfiddich TV Programme of the Year Award 2001 Jacob's Creek World Food Media Awards: Silver for best Television Food Show Friends for Dinner, BBC TV, 2000 Rick Stein on Fishing, ITV, 2001 Rick Stein's Food Heroes, BBC TV, 2002. 10 episodes – Jacob's Creek World Food Media Awards 2003: Gold for Best Television Food Show Rick Stein's Food Heroes, Another Helping, Series 1, BBC TV, October 2003. 6 episodes Rick Stein's Food Heroes, Another Helping, Series 2, BBC TV, February 2004. 8 episodes Rick Stein's Fish Love, UKTV Fish, August 2004 Rick Stein's French Odyssey, BBC TV, May 2005. 10 episodes Cabin Fever (Behind the scenes and the making of Rick Stein's French Odyssey), BBC TV, Autumn 2005. single 1-hour programme.
The insulin concentration in blood increases after meals and gradually returns to basal levels during the next 1–2 hours. However, the basal insulin level is not stable. It oscillates with a regular period of 3-6 min. After a meal the amplitude of these oscillations increases but the periodicity remains constant. The oscillations are believed to be important for insulin sensitivity by preventing downregulation of insulin receptors in target cells. Such downregulation underlies insulin resistance, which is common in type 2 diabetes. It would therefore be advantageous to administer insulin to diabetic patients in a manner mimicking the natural oscillations. The insulin oscillations are generated by pulsatile release of the hormone from the pancreas. Insulin originates from beta cells located in the islets of Langerhans. Since each islet contains up to 2000 beta cells and there are one million islets in the pancreas it is apparent that pulsatile secretion requires sophisticated synchronization both within and among the islets of Langerhans.
Sources: en.wikipedia.org
Jake Melksham (born 29 August 1991) is a former professional Australian rules footballer who played for Melbourne Football Club and the Essendon Football Club in the Australian Football League (AFL). A midfielder, 1.86 metres (6 ft 1 in) tall and weighing 83 kilograms (183 lb), Melksham also has the ability to play as a defender, primarily as a half-back flanker. Growing up in Glenroy, Victoria, he played top-level football early when he joined the Calder Cannons' under 18 side in the TAC Cup at the age of sixteen. He spent three years playing for the Calder Cannons, winning a premiership in his final junior year. His achievements as a junior include state representation and the TAC Medal as the best player on the ground in the TAC Cup Grand Final. Melksham's late surge in his draft year saw him recruited by the Essendon Football Club with the tenth selection in the 2009 AFL draft. He made his AFL debut in the 2010 season and was rewarded with an AFL Rising Star nomination. He spent six seasons with Essendon, which peaked with a fifth-place finish in the best and fairest, and after 114 games with the club, he was traded to the Melbourne Football Club during the 2015 trade period. Before he could play his first match with Melbourne, he was suspended for the 2016 season for his involvement in the Essendon Football Club supplements saga; he was the last remaining player involved in the saga at the time of his retirement in 2026. In November 2023 he was delisted by the Melbourne Football Club, then re-listed in the subsequent rookie draft.
Bremelanotide was first developed by Palatin Technologies, then out-licensed to AMAG Pharmaceuticals Inc. after its approval by the FDA on 21 June 2019. Marked as VyleesiTM, it was primarily designed for both men and women in the form of an intranasal formulation, particularly for treating male erectile dysfunction. However, the research was discontinued and focused on targeting female HSDD in a subcutaneous injection to increase bioavailability. Bremelanotide is usually injected a minimum of 45 minutes before sexual activity. Despite having identical prescription criteria as that of flibanserin, bremelanotide is not recommended for pregnant patients. No trial was tested on pregnant patients. Therefore, patients at childbearing ages are recommended to use contraception continuously during treatment and should discontinue once they become pregnant.
The longest dictionary form word is the word megszentségtelenített, with 21 characters (although it ultimately derives from the word szent meaning: "saint" or "sacred"), and it means "desecrated" or "profaned".
They present covalent cross-linkages between the polypeptide chains. These bonds are the strongest because they're covalent bonds, making them stronger than intermolecular forces. Glycosylation is another way to improve the thermostability of proteins. Stereoelectronic effects in stabilizing interactions between carbohydrate and protein can lead to the thermostabilization of the glycosylated protein. Cyclizing enzymes by covalently linking the N-terminus to the C-terminus has been applied to increase the thermostability of many enzymes. Intein cyclization and SpyTag/SpyCatcher cyclization have often been employed.
=== New Zealand and Australia === Sales of A1 protein-free milk in Australia and New Zealand boosted significantly following 2007, after the publication of a book, Devil in the Milk by Keith Woodford, about A1 beta-casein and its perceived dangers to health; the book prompted the New Zealand Food Safety Authority to propose again reviewing the science to address consumer concerns that milk containing both the A1 and A2 proteins might be harmful. It asked the European Food Safety Authority (EFSA) to undertake such a review. The EFSA report, released in 2009, found that "a cause and effect relationship is not established between the dietary intake of BCM7 (beta-casomorphin-7), related peptides or their possible protein precursors and non-communicable diseases". The a2 Milk Company launched an infant formula in New Zealand and Australia in September 2013 and an A1 protein-free thickened cream was launched in January 2014 under the a2 and a2 MILK brands. A2 Corporation changed its name to the a2 Milk Company Limited effective April 2014, and at that time had about 8% market share of the milk products market in Australia. In 2014 Lion, a beverage and food company that operates in Australia and New Zealand and is owned by Kirin, relaunched its Pura Milk product with a new label stating: "Naturally contains A2 protein." The a2 Milk Company announced in November 2014 that it had begun the application process for a dual listing on the Australian Securities Exchange in a bid to open its register to Australian investors and boost the liquidity of its shares.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.